Cystic Fibrosis, Clinical Trials & COVID-19
Dr Damian Downey gives an overview of some recent papers on COVID-19 and cystic fibrosis (CF) and the impact of lockdown on CF. He then continues with what can research sites and clinical trial network do. Additionally, in this presentation, Dr Downey provides updates on the therapeutic development network data on the impact of SARS-CoV-2 on clinical trials, presents a summary of the COVID-19 antibody response in CF (CAR-CF study) and discusses the challenges of the CF clinical research ahead.
We hope that you found the content valuable. To ensure that we continue to provide topics and content of interest, we would very much value your feedback by completing a short questionnaire.
Dr Damian Downey
Dr Downey is an academic CF physician at Queen’s University Belfast and the N. Ireland Regional Adult CF Centre in Belfast. He trained in CF and respiratory medicine in Belfast, Manchester and Brisbane. His research focus is to optimise clinical response to established and new therapies and leads an active investigator-initiated and pharmaceutical-sponsored research program to help realise this. He is co-director of the European CF Clinical Trials Network.